Glecaprevir/Pibrentasvir

Pronunciation: gleh-KAP-reh-veer and pib-REN-tas-veer.

Generic name
glecaprevir and pibrentasvir
Drug class
Direct-acting antiviral (DAA) combination: NS3/4A protease inhibitor (glecaprevir) plus NS5A inhibitor (pibrentasvir)
Form
Film-coated tablet (100 mg/40 mg); oral pellets/coated granules (50 mg/20 mg per packet/sachet) for younger or lower-weight children
Route
Oral
Legal status
Prescription-only

Availability and supply rules vary by country

Trade names by country: United States · United Kingdom · Canada · Australia · New Zealand

Australia: Maviret (5) · Full directory

What glecaprevir and pibrentasvir is and how it works

Glecaprevir/pibrentasvir is a prescription-only, once-daily tablet combination that treats chronic (and, where approved, acute) hepatitis C virus (HCV) infection across all major HCV genotypes (1 through 6), usually taken for 8 to 16 weeks. (1) (3)

You take three tablets once a day with food, for a course your prescriber sets based on your HCV genotype, whether you have cirrhosis, and whether you've been treated for hepatitis C before. Because it can reactivate hepatitis B virus in some people, your prescriber tests you for hepatitis B before you start and monitors you if you have ever had it.

Mechanism of action: how glecaprevir and pibrentasvir works

Glecaprevir is an inhibitor of the HCV NS3/4A protease, required for proteolytic cleavage of the HCV-encoded polyprotein. Pibrentasvir is an inhibitor of the HCV NS5A protein, required for viral RNA replication and virion assembly. Together they provide pangenotypic (genotype 1-6) antiviral activity. (1) (3)

What glecaprevir and pibrentasvir is used for

Chronic hepatitis C virus infection, genotypes 1-6

Used to treat chronic HCV infection across all six major genotypes in adults and children, with or without compensated (mild) cirrhosis, usually for 8 weeks if you have not been treated for hepatitis C before. (1) (2)

Acute hepatitis C virus infection

In the US, UK, EU, and New Zealand, also approved for newly acquired (acute) HCV infection, not just longstanding (chronic) infection. (1) (3) (6)

Previously treated hepatitis C (genotype 1, and limited genotype 4)

Used for genotype 1 (and a very limited number of genotype 4) infections in people who were previously treated with either an NS5A inhibitor or an NS3/4A protease inhibitor (but not both classes) -- typically for a longer, 16-week course. (1) (3)

Liver or kidney transplant recipients

Used for 12 weeks (16 weeks in some genotype 3, treatment-experienced cases) in people who have had a liver or kidney transplant and have HCV infection. (3) (6)

Before taking glecaprevir and pibrentasvir

Do not take / not appropriate for

  • Do not take glecaprevir/pibrentasvir if you have moderate or severe liver impairment (Child-Pugh B or C) or a history of liver decompensation -- it is contraindicated in the US and contraindicated (severe) or not recommended (moderate) in the UK/EU/New Zealand. (all countries) (1) (3) (6)
  • Do not take glecaprevir/pibrentasvir together with atazanavir or rifampin (rifampicin) -- this combination is contraindicated in every market reviewed. (all countries) (1) (3) (6)
  • In the UK and EU, also do not take with atorvastatin, simvastatin, dabigatran etexilate, ethinyl estradiol-containing products (e.g. some combined contraceptives), or strong P-gp/CYP3A inducers such as carbamazepine, phenytoin, phenobarbital, primidone, or St John's wort. (United Kingdom and European Union) (2) (3)
  • Do not take if you have had an allergic reaction to glecaprevir, pibrentasvir, or any of the other ingredients. (all countries) (1) (3)

Tell your clinician about

  • Any history of hepatitis B infection, or if you don't know your hepatitis B status -- you will be tested before starting.
  • Any liver disease or history of liver problems, including cirrhosis.
  • Whether you have diabetes -- your blood sugar control may improve during treatment, which can occasionally cause low blood sugar; your diabetes medicines may need adjusting.
  • All other medicines you take, especially statins, dabigatran, hormonal contraceptives, anti-seizure medicines, HIV medicines, or St John's wort.
  • If you have galactose intolerance, lactase deficiency, or glucose-galactose malabsorption -- the tablets contain lactose.
  • Pregnancy, plans for pregnancy, or breastfeeding.
  • Whether you have had a liver or kidney transplant, or have been treated for hepatitis C before.
(1) (2) (3)

How to take glecaprevir and pibrentasvir

  • Swallow the three tablets whole, once a day, at the same time each day, with food -- do not chew, crush, or break them.
  • Do not change your dose, stop early, or extend treatment on your own -- your prescriber sets the exact number of weeks based on your genotype, cirrhosis status, and treatment history.
  • Children aged 3 to under 12 years (where approved) use a weight-based oral pellet/granules formulation instead of tablets -- the two formulations are not interchangeable.
  • Your prescriber will test you for hepatitis B before your first dose.
(1) (3)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1) (2) (3) (4) (5) (6)

Missed dose

If you miss a dose, you can still take it if less than 18 hours have passed since your usual dosing time. If more than 18 hours have passed, skip the missed dose and take your next dose at the usual time the next day -- never take a double dose. If you vomit within 3 hours of taking a dose, take another dose; if vomiting happens more than 3 hours after dosing, no extra dose is needed. Contact your prescriber if you're unsure.

Overdose

Seek urgent medical attention if too much glecaprevir/pibrentasvir may have been taken, or if you develop signs of liver problems (such as yellowing skin/eyes, dark urine, or unusual tiredness) after a dose. (1)

Side effects

Side effects and their urgency vary; report severe, persistent, or concerning symptoms.

Headache -- very common, generally mild to moderate.

What to notice: Headache -- very common, generally mild to moderate.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Fatigue (tiredness) -- very common, generally mild to moderate.

What to notice: Fatigue (tiredness) -- very common, generally mild to moderate.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Nausea.

What to notice: Nausea.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (3)

Diarrhoea.

What to notice: Diarrhoea.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (3)

In children under 12 years: vomiting, rash, and upper abdominal pain occurred more often than in adults.

What to notice: In children under 12 years: vomiting, rash, and upper abdominal pain occurred more often than in adults.

What to do: Discuss persistent or troublesome symptoms with the treating clinician or pharmacist. (1)

Serious warnings

Signs of hepatitis B reactivation or liver injury — boxed_warning

Symptoms: Yellowing of the skin or eyes, dark urine, unusual tiredness, loss of appetite, nausea, vomiting, or pain in the upper right side of the abdomen.

Action: Contact your prescriber immediately or seek urgent medical care. You will be tested for hepatitis B before starting, and monitored during and after treatment if you have ever had hepatitis B -- reactivation can be fatal if not managed promptly. (1) (3)

Signs of worsening liver disease (hepatic decompensation) — high caution

Symptoms: Confusion, worsening jaundice, swelling of the abdomen or legs, or vomiting blood.

Action: Seek urgent medical attention. This medicine is not recommended or is contraindicated in more advanced liver disease; your prescriber will monitor your liver function during treatment. (1) (3)

Low blood sugar symptoms (in people with diabetes) — high caution

Symptoms: Shakiness, sweating, confusion, or dizziness.

Action: Check your blood sugar and tell your prescriber -- clearing the hepatitis C virus can improve liver function and glucose control, occasionally causing symptomatic hypoglycaemia; your diabetes medicines may need adjusting. (2) (3)

Signs of a serious allergic reaction — emergency

Symptoms: Swelling of the face, lips, tongue, or throat; difficulty breathing; widespread rash or hives.

Action: Seek emergency medical help immediately. (1)

Interactions

  • Atazanavir and rifampin (rifampicin) must not be taken with glecaprevir/pibrentasvir in any market reviewed -- these combinations are contraindicated. (1) (3) (6)
  • Statins (especially atorvastatin and simvastatin) can build up to higher levels -- not recommended in the UK/EU; in markets where allowed, doses of rosuvastatin and pravastatin may need reducing. (1) (3)
  • Digoxin levels can rise -- your prescriber may reduce your digoxin dose by about half. (1) (3)
  • Dabigatran levels can rise significantly -- combined use is contraindicated (UK/EU) or not recommended (US). (2) (3)
  • Strong P-gp/CYP3A inducers (carbamazepine, efavirenz, phenytoin, phenobarbital, primidone, St John's wort) can reduce glecaprevir/pibrentasvir levels and the treatment's effectiveness -- avoid combining. (1) (3)
  • Ethinyl estradiol-containing hormonal contraceptives above 20 micrograms are not recommended (US) or contraindicated (UK/EU) due to a risk of raised liver enzymes; lower-dose products (20 mcg or less) may be acceptable in some markets -- discuss contraception options with your prescriber. (1) (3)
  • If you take a vitamin K antagonist (e.g. warfarin), your INR should be monitored closely, since liver function can change during treatment. (3) (6)
  • Ciclosporin at stable doses above 100 mg/day is not recommended with this medicine. (3)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

There is no adequate human data on use in pregnancy. Animal studies did not show adverse effects at exposures well above human therapeutic doses, but this has not been confirmed in humans. Discuss with your prescriber if you are pregnant or planning pregnancy. (1) (2) (3) (4) (5) (6)

Breastfeeding

It is not known whether glecaprevir or pibrentasvir pass into human breast milk. Discuss the balance of benefits and risks with your prescriber before breastfeeding during treatment. (1) (2) (3) (4) (5) (6)

Children

Approved from age 3 years (weight-based oral pellets/granules, 12 kg or more) in the US, UK, EU, Canada, and Australia. The current New Zealand data sheet authorises use only from age 12 years -- safety and efficacy under 12 years have not been established there. Not studied under 3 years, or under 12 kg, in any market. (1) (2) (3) (4) (5) (6)

Hepatic_impairment

No dose adjustment needed for mild impairment (Child-Pugh A). Not recommended in moderate impairment (Child-Pugh B) and contraindicated in severe impairment (Child-Pugh C) or with a history of liver decompensation. (1) (2) (3) (4) (5) (6)

Renal_impairment

No dose adjustment is needed for any degree of kidney impairment, including people on dialysis. (1) (2) (3) (4) (5) (6)

Source_ids

US-DAILYMED-MAVYRET-2026,EU-EMA-MAVIRET-SMPC-2026,NZ-MEDSAFE-MAVIRET-2026 (1) (2) (3) (4) (5) (6)

Monitoring

Before starting

  • Hepatitis B testing (HBsAg and anti-HBc) in all patients
  • Liver function assessment, including Child-Pugh classification
  • HCV genotype and cirrhosis status confirmation
  • Review of all other medicines, especially statins, dabigatran, hormonal contraceptives, and anti-seizure medicines
  • Blood glucose review in people with diabetes

During treatment

  • Monitoring for signs of hepatitis flare or HBV reactivation in people with current or past hepatitis B infection.
  • Monitoring for signs of worsening liver disease, especially in people with any pre-existing liver impairment.
  • Blood glucose monitoring in people with diabetes, particularly in the first 3 months.
  • INR monitoring if taking a vitamin K antagonist.
(1) (3)

Storage

Store at room temperature, in the original container, protected from moisture. Keep the desiccant in the bottle. Do not use after the expiry date printed on the pack.

Professional information

Clinician-facing context only, sourced from the current US FDA prescribing information and EU SmPC; verify against the current full label in the relevant jurisdiction before prescribing.

United States

Indication: Acute or chronic HCV genotypes 1-6, with or without compensated cirrhosis; ages 3+

Dose summary: 300 mg/120 mg once daily with food. Treatment-naive: 8 weeks. Genotype 1 (or limited genotype 4) with prior NS5A-inhibitor failure: 16 weeks; prior NS3/4A-PI failure: 12 weeks. Pediatric 3-<12y: weight-based pellets.

Renal context: No dose adjustment at any degree of renal impairment, including dialysis. (1)

European Union / United Kingdom

Indication: Acute and chronic HCV genotypes 1-6 (EU); chronic HCV (UK label); ages 3+

Dose summary: 300 mg/120 mg once daily with food. Treatment-naive: 8 weeks (all genotypes). Treatment-experienced (peg-IFN+ribavirin +/- sofosbuvir, or sofosbuvir+ribavirin): genotypes 1,2,4-6 8 weeks (no cirrhosis)/12 weeks (cirrhosis); genotype 3 16 weeks. Transplant recipients: 12 weeks (16 weeks if genotype 3 treatment-experienced or NS5A-experienced).

Renal context: No dose adjustment at any degree of renal impairment, including dialysis. (3) (2)

New Zealand

Indication: Acute or chronic HCV, ages 12 and older only (narrower pediatric floor than the other 5 markets reviewed)

Dose summary: 300 mg/120 mg once daily with food; same genotype/duration tables as the EU. Tablets only -- no pediatric weight-based formulation currently referenced in the NZ data sheet.

Renal context: No dose adjustment at any degree of renal impairment, including dialysis. (6)

Mechanism of action

Hepatic guidance

No adjustment for mild impairment (Child-Pugh A); not recommended in moderate (Child-Pugh B); contraindicated in severe (Child-Pugh C) or prior decompensation history.

Overdose note

Limited overdose experience reported; manage supportively with monitoring of liver function. (1) (3)

Frequently asked questions

Is glecaprevir/pibrentasvir (Mavyret/Maviret) available in the US, UK, Europe, Canada, Australia, and New Zealand?

Yes, it is approved and available in all of these regions, as Mavyret in the United States and Maviret elsewhere, for chronic hepatitis C in adults, and for acute hepatitis C in the US, UK, EU, and New Zealand. (1) (2) (3) (4) (5) (6)

Why do I need a hepatitis B test before starting this medicine?

Glecaprevir/pibrentasvir carries a boxed (highest-level) FDA warning because it can cause hepatitis B virus to reactivate in people who currently have it or have had it in the past, in rare cases leading to serious liver injury or death. Testing beforehand lets your prescriber monitor you closely if you test positive. (1)

Is this medicine approved for children at the same age everywhere?

No. In the US, UK, EU, Canada, and Australia, it's approved from age 3 (using a weight-based oral pellet/granules formulation for younger or smaller children). The current New Zealand data sheet only covers ages 12 and older -- safety and efficacy under 12 have not been established there. This is a genuine difference between regulators, not an error. (1) (6)

How long will I need to take it for?

Usually 8 weeks if you have not been treated for hepatitis C before. It can be longer -- 12 or 16 weeks -- depending on your HCV genotype, whether you have cirrhosis, whether you've had hepatitis C treatment before, and whether you've had a liver or kidney transplant. Your prescriber will set the exact duration. (1) (3)

What is the mechanism of action of glecaprevir and pibrentasvir?

Glecaprevir is an inhibitor of the HCV NS3/4A protease, required for proteolytic cleavage of the HCV-encoded polyprotein. Pibrentasvir is an inhibitor of the HCV NS5A protein, required for viral RNA replication and virion assembly. Together they provide pangenotypic (genotype 1-6) antiviral activity. (1) (3)

What is the generic name of Glecaprevir/Pibrentasvir?

The generic name is glecaprevir and pibrentasvir. (1) (3)

What class of drug is glecaprevir and pibrentasvir?

Glecaprevir/Pibrentasvir is classed as: Direct-acting antiviral (DAA) combination: NS3/4A protease inhibitor (glecaprevir) plus NS5A inhibitor (pibrentasvir). (1) (3)

References

  1. MAVYRET (glecaprevir and pibrentasvir) tablets and oral pellets -- full prescribing informationU.S. Food and Drug Administration / DailyMed (NIH), full prescribing information, AbbVie Inc. · United States · accessed 2026-07-30 · source 1
  2. Glecaprevir/Pibrentasvir (Maviret) 100 mg/40 mg film-coated tablets -- Summary of Product Characteristicselectronic medicines compendium (emc), United Kingdom -- AbbVie Ltd · United Kingdom · accessed 2026-07-30 · source 2
  3. Maviret 100 mg/40 mg film-coated tablets -- Summary of Product CharacteristicsEuropean Medicines Agency (EMA) -- Maviret Annex I Summary of Product Characteristics (EPAR) · European Union · accessed 2026-07-30 · source 3
  4. MAVIRET (glecaprevir/pibrentasvir) Product MonographHealth Canada product monograph, AbbVie Corporation · Canada · accessed 2026-07-30 · source 4
  5. MAVIRET glecaprevir/pibrentasvir 100mg/40mg film-coated tablet and granules sachet -- ARTG entriesTherapeutic Goods Administration (TGA), Australia · Australia · accessed 2026-07-30 · source 5
  6. MAVIRET New Zealand Data Sheet (MAVIRET DS v13, CCDSv11, 22 October 2025)Medsafe (New Zealand regulator) · New Zealand · accessed 2026-07-30 · source 6

Brand names by country

Single-ingredient glecaprevir and pibrentasvir names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.

Priority countries

United States

  • Mavyret (1)FDA approved currently labeled since 2017 · 100 mg/40 mg film-coated tablet, 50 mg/20 mg oral pellet packet · AbbVie Inc.

United Kingdom

  • Maviret (2)MHRA licensed emc smpc confirmed · 100 mg/40 mg film-coated tablet, 50 mg/20 mg coated granules sachet · AbbVie Ltd

Canada

  • Maviret (4)Health Canada approved confirmed DIN 02467550 · 100 mg/40 mg tablet, 50 mg/20 mg oral granules sachet · AbbVie Corporation

Australia

  • Maviret (5)TGA ARTG registered 2018-01-02 confirmed · 100 mg/40 mg film-coated tablet (ARTG 325401), 50 mg/20 mg granules sachet (ARTG 352573) · AbbVie Pty Ltd

New Zealand

  • Maviret (6)Medsafe approved confirmed via current NZ data sheet tablet only ages 12 plus · 100 mg/40 mg film-coated tablet · AbbVie Limited (New Zealand)
View brands in additional countries.

European Union

Maviret (3)

This page provides general reference information about glecaprevir/pibrentasvir (Mavyret/Maviret) and is not a substitute for advice from the prescriber managing your treatment. All dosing, screening, and treatment decisions should be made with your prescriber.

Related medicines